LONDON, United Kingdom and BUELACH, Switzerland,
27
April
2017
|
00:00
Europe/Amsterdam

New Data Show Efficacy of Pulsar-18 Bare Metal Stent; Combination with Passeo-18 Lux DCB Challenges Results with Drug-Eluting Stents

BIOTRONIK’s Bare Metal Stent Proves Effective and Versatile as Standalone and in Combination with Drug-Coated Balloon in 12-Month Results of BIOFLEX PEACE and BIOLUX 4EVER

BIOTRONIK’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the 12-month results of the BIOFLEX PEACE all-comers registry. The findings were presented yesterday at the Charing Cross Symposium in London. Outcomes of the BIOLUX 4EVER study were also presented on the main stage, revealing 12-month results numerically comparable to drug-eluting stents (DES) when the Pulsar-18 was used in combination with the Passeo-18 Lux drug-coated balloon (DCB).

 

 

About BIOTRONIK:

BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.